Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1634-1642

  Kathawala, Rishil J ^a   Chen, Jun Jiang ^a   Zhang, Yun Kai ^a   Wang, Yi Jun ^a   Patel, Atish ^a   Wang, De Shen ^a,b   Talele, Tanaji T ^a   Ashby Jr , Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ATP binding cassette subfamily G member 2; Masitinib; Multi drug resistance; Tyrosine kinase inihibitors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOXORUBICIN; FIRTECAN; MASITINIB; MITOXANTRONE; NILOTINIB;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; HEK293 CELLS; HUMANS; MITOXANTRONE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; THIAZOLES;

EID: 84899070719     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2341     Document Type: Article

References (79)

1. Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105, 2008.
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
3. Quintieri L, Fantin M and Vizler C: Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv Exp Med Biol 593: 95-104, 2007.
4. Liu YY, Han TY, Giuliano AE and Cabot MC: Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730, 2001. (Pubitemid 32245990)
5. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993. (Pubitemid 23289454)
6. Synold TW, Dussault I and Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7: 584-590, 2001. (Pubitemid 32448326)
7. Deeley RG, Westlake C and Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006. (Pubitemid 44033384)
8. Bradbury PA and Middleton MR: DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15: 421-426, 2004. (Pubitemid 38736939)
9. Ambudkar SV, Kim IW, Xia D and Sauna ZE: The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett 580: 1049-1055, 2006. (Pubitemid 43185285)
10. Liu FS: Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J Obstet Gynecol 48: 239-244, 2009.
11. Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262, 2007. (Pubitemid 46899341)
12. Linton KJ and Higgins CF: Structure and function of ABC transporters: the ATP switch provides flexible control. Pflugers Arch 453: 555-567, 2007. (Pubitemid 46192529)
13. Sodani K, Patel A, Kathawala RJ and Chen ZS: Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 31: 58-72, 2012.
14. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr and Chen ZS: Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12: 570-594, 2011.
15. Mao Q and Unadkat JD: Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7: E118-E133, 2005. (Pubitemid 41554295)
16. Suzuki M, Suzuki H, Sugimoto Y and Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278: 22644-22649, 2003. (Pubitemid 36830322)
17. Rocchi E, Khodjakov A, Volk EL, et al: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 271: 42-46, 2000. (Pubitemid 30444853)
18. Maliepaard M, Scheffer GL, Faneyte IF, et al: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458-3464, 2001. (Pubitemid 32695041)
19. Cooray HC, Blackmore CG, Maskell L and Barrand MA: Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13: 2059-2063, 2002. (Pubitemid 36005925)
20. Doyle LA, Yang W, Abruzzo LV, et al: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998. (Pubitemid 29018757)
21. Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29, 2003. (Pubitemid 36078452)
22. Dean M and Allikmets R: Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33: 475-479, 2001. (Pubitemid 34052573)
23. Miyake K, Mickley L, Litman T, et al: Molecular cloning of cDNAs which are highly overexpressed in mitoxantroneresistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999. (Pubitemid 29062946)
24. Chen ZS, Robey RW, Belinsky MG, et al: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63: 4048-4054, 2003. (Pubitemid 36917926)
25. Honjo Y, Hrycyna CA, Yan QW, et al: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639, 2001. (Pubitemid 32896477)
26. Dai CL, Liang YJ, Wang YS, et al: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 279: 74-83, 2009.
27. Pozza A, Perez-Victoria JM, Sardo A, Ahmed-Belkacem A and Di Pietro A: Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell Mol Life Sci 63: 1912-1922, 2006.
28. Ejendal KF and Hrycyna CA: Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3: 503-511, 2002. (Pubitemid 35157721)
29. Padmanabhan R, Chen KG, Gillet JP, et al: Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells 30: 2175-2187, 2012.
30. Evseenko DA, Paxton JW and Keelan JA: Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35: 595-601, 2007. (Pubitemid 46513262)
31. Chen ZS, Aoki S, Komatsu M, et al: Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer 93: 107-113, 2001. (Pubitemid 32539509)
32. Dai CL, Tiwari AK, Wu CP, et al: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914, 2008.
33. Kathawala RJ, Wang YJ, Ashby Jr CR and Chen ZS: Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin J Cancer: Oct 9, 2013 (Epub ahead of print).
34. Deng W, Dai CL, Chen JJ, et al: Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncol Rep 29: 2479-2485, 2013.
35. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006. (Pubitemid 43336035)
36. Yang D, Kathawala RJ, Chufan EE, et al: Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncol: Dec 3, 2013 (Epub ahead of print).
37. Shen T, Kuang YH, Ashby CR, et al: Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 4: e7520, 2009.
38. Tiwari AK, Sodani K, Wang SR, et al: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78: 153-161, 2009.
39. Shi Z, Peng XX, Kim IW, et al: Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67: 11012-11020, 2007. (Pubitemid 350145931)
40. Vermersch P, Benrabah R, Schmidt N, et al: Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 12: 36, 2012.
41. Rommer PS and Stuve O: Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol 15: 241-258, 2013.
42. Humbert M, de Blay F, Garcia G, et al: Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64: 1194-1201, 2009.
43. Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, DeClue AE and Reinero CR: The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol 158: 369-374, 2012.
44. Tebib J, Mariette X, Bourgeois P, et al: Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, openlabel, dose-ranging, phase 2a study. Arthritis Res Ther 11: R95, 2009.
45. Walker UA: More about masitinib. Arthritis Res Ther 11: 120, 2009.
46. Georgin-Lavialle S, Lhermitte L, Suarez F, et al: Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 89: 47-52, 2012.
47. Paul C, Sans B, Suarez F, et al: Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85: 921-925, 2010.
48. Le Cesne A, Blay JY, Bui BN, et al: Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 46: 1344-1351, 2010.
49. Mitry E, Hammel P, Deplanque G, et al: Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 66: 395-403, 2010.
50. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
51. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG and Chen ZS: ABCC10, ABCC11, and ABCC12. Pflugers Arch 453: 675-684, 2007. (Pubitemid 46192538)
52. Robey RW, Honjo Y, Morisaki K, et al: Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89: 1971-1978, 2003. (Pubitemid 37533279)
53. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
54. Hazai E and Bikadi Z: Homology modeling of breast cancer resistance protein (ABCG2). J Struct Biol 162: 63-74, 2008.
55. Alqawi O, Bates S and Georges E: Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem J 382: 711-716, 2004. (Pubitemid 39243937)
56. Sun YL, Kathawala RJ, Singh S, et al: Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Anticancer Drugs 23: 865-873, 2012.
57. Litman T, Brangi M, Hudson E, et al: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000. (Pubitemid 30386505)
58. Schellens JH, Maliepaard M, Scheper RJ, et al: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922: 188-194, 2000. (Pubitemid 32050253)
59. Jonker JW, Smit JW, Brinkhuis RF, et al: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1651-1656, 2000.
60. Nakamura Y, Oka M, Soda H, et al: Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546, 2005. (Pubitemid 40270183)
61. Shukla S, Robey RW, Bates SE and Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37: 359-365, 2009.
62. Mi YJ, Liang YJ, Huang HB, et al: Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 70: 7981-7991, 2010.
63. Nicolle E, Boumendjel A, Macalou S, et al: QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev 61: 34-46, 2009.
64. An Y and Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5: 1529-1542, 2009.
65. Chen YJ, Huang WC, Wei YL, et al: Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One 6: e21428, 2011.
66. Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83: 1084-1103, 2012.
67. Kerr ID, Haider AJ and Gelissen IC: The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br J Pharmacol 164: 1767-1779, 2011.
68. Robey RW, Medina-Perez WY, Nishiyama K, et al: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145-152, 2001. (Pubitemid 32110217)
69. Robey RW, Ierano C, Zhan Z and Bates SE: The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 12: 595-608, 2011.
70. Woodward OM, Kottgen A and Kottgen M: ABCG transporters and disease. FEBS J 278: 3215-3225, 2011.
71. Xu J, Peng H and Zhang JT: Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem 14: 689-701, 2007. (Pubitemid 46477721)
72. Hang D, Dong HC, Ning T, Dong B, Hou DL and Xu WG: Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus 25: 638-644, 2012.
73. Li J, Li ZN, Du YJ, Li XQ, Bao QL and Chen P: Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 10: 414-421, 2009.
74. Tsunoda S, Okumura T, Ito T, et al: ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71: 251-258, 2006.
75. Bunting KD: ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20: 11-20, 2002.
76. Kim M, Turnquist H, Jackson J, et al: The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 22-28, 2002. (Pubitemid 34101455)
77. Kusuhara H and Sugiyama Y: ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453: 735-744, 2007. (Pubitemid 46192543)
78. Ding XW, Wu JH and Jiang CP: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-637, 2010.
79. Sung JM, Cho HJ, Yi H, et al: Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371: 163-167, 2008.